Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.37 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 14.44 | 5.69 | 41.97 | 14.98 | 39.19 | 42.73 | 29.45 | 29.73 | 33.30 | 45.25 | 50.45 | 46.40 | 44.49 |
| — | -86.7% | +42.5% | -49.6% | +17.7% | -5.6% | -41.6% | -35.9% | -25.1% | +27.8% | +555.0% | +181.1% | +1755.2% | |
| P/B Ratio | 1.12 | 1.06 | 1.56 | 1.02 | 0.65 | 0.82 | 0.71 | 0.78 | 1.17 | 1.44 | 1.13 | 1.56 | 1.80 |
| — | +29.3% | +119.3% | +29.7% | -44.7% | -43.3% | -36.8% | -49.8% | -34.6% | -41.7% | -54.9% | -37.5% | -28.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
AbCellera Biologics Inc.'s operating margin was -253.2% in Q4 2025, up 598.6 pp QoQ and up 1187.5 pp YoY. The trailing four-quarter average of -718.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 232.5% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | -132.5% | 100.0% | 58.7% | 100.0% | 100.0% | -488.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -232.5% | +120.5% | -41.3% | 0.0% | 0.0% | -588.5% | 0.0% | 0.0% | +7.8% | +17.4% | +12.8% | +16.4% | |
| Operating Margin | -289.0% | -253.2% | -851.8% | -290.2% | -1479.6% | -1440.7% | -1439.4% | -1276.2% | -551.5% | -719.6% | -831.8% | -511.0% | -532.1% |
| — | +82.4% | +40.8% | +77.3% | -168.3% | -100.2% | -73.1% | -149.7% | -3.6% | -310.4% | -2334.8% | -2694.8% | -848.8% | |
| Net Margin | -194.9% | -19.9% | -637.8% | -203.3% | -1077.2% | -677.4% | -785.4% | -504.3% | -408.0% | -513.7% | -433.6% | -303.6% | -329.0% |
| — | +97.1% | +18.8% | +59.7% | -164.0% | -31.9% | -81.2% | -66.1% | -24.0% | -270.2% | -1750.9% | -1954.5% | -717.8% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.5% | -0.9% | -5.8% | -3.4% | -4.4% | -3.2% | -4.7% | -3.3% | -3.6% | -4.0% | -2.4% | -2.5% | -3.3% |
| — | +71.1% | -24.1% | -3.8% | -23.3% | +20.6% | -94.0% | -29.7% | -8.3% | -67.7% | -211.3% | -353.1% | -121.8% | |
| ROA | -14.7% | -0.9% | -4.1% | -2.5% | -3.4% | -2.5% | -3.6% | -2.6% | -2.8% | -3.1% | -1.9% | -2.0% | -2.6% |
| — | +63.7% | -13.7% | +1.5% | -22.6% | +20.9% | -94.2% | -27.7% | -4.3% | -62.6% | -210.9% | -372.3% | -122.8% | |
| ROIC | -16.8% | -8.5% | -5.5% | -3.7% | -5.0% | -5.5% | -6.8% | -6.6% | -3.8% | -4.5% | -3.8% | -3.5% | -4.8% |
| — | -55.3% | +19.4% | +43.6% | -31.0% | -21.2% | -81.6% | -89.0% | +21.2% | -50.5% | -193.9% | -223.4% | -118.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 15.5% YoY to 11.32x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | 0.15 | 0.14 | 0.07 | 0.06 | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| — | +129.6% | +122.8% | +117.5% | +1.8% | -7.8% | -3.0% | -7.8% | -5.3% | +0.7% | +12.2% | +131.9% | +106.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.32 | 11.32 | 10.10 | 11.07 | 10.15 | 9.81 | 9.34 | 10.96 | 7.76 | 7.33 | 8.34 | 7.83 | 10.50 |
| — | +15.5% | +8.2% | +1.0% | +30.7% | +33.9% | +11.9% | +40.1% | -26.1% | -15.5% | -15.4% | +51.3% | +90.8% | |
| Quick Ratio | 11.32 | 11.32 | 10.10 | 11.07 | 10.15 | 9.81 | 9.34 | 10.96 | 7.75 | 7.32 | 8.33 | 7.82 | 10.48 |
| — | +15.5% | +8.2% | +1.0% | +30.9% | +34.0% | +12.1% | +40.3% | -26.0% | -15.4% | -13.4% | +54.5% | +94.7% | |
| Interest Coverage | — | -7.05 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAbCellera Biologics Inc.'s current P/E is -7.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AbCellera Biologics Inc.'s current operating margin is -289.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AbCellera Biologics Inc.'s business trajectory between earnings reports.